Proton pump inhibitors (PPIs) such as omeprazole, esomeprazole and pantoprazole are linked to a modestly higher risk of fractures, especially with high doses or use for a year or longer. Whether they actually cause bone density to fall is much less certain. If you have osteopenia or osteoporosis and take a PPI, the practical answer is not to stop on your own. Ask your prescriber whether you still need it, whether the dose can be lower, and whether your bones need closer monitoring.
TL;DR
- The FDA labeling for PPIs says therapy may be associated with a higher risk of osteoporosis-related fractures of the hip, wrist or spine. The risk is higher with multiple daily doses and with a year or more of use.
- The link is stronger for fractures than for measured bone density loss. Large reviews rate much of the evidence as low certainty, and causation is not settled.
- Do not stop a PPI abruptly. Ask whether you still need it, and whether the lowest effective dose is enough.
- If you take a PPI long term and have osteopenia, osteoporosis, or other fracture risk factors, ask about a bone density scan, vitamin D, calcium and magnesium status.
- Strength-based habits protect bone whatever medication you take, including weekly osteogenic loading, which we offer.
Table of Contents
- What PPIs are and why bone health comes up
- What the fracture research shows
- Does it actually reduce bone density?
- How PPIs might affect bone
- Who should pay closer attention
- What to do if you take a PPI
- Protecting bone while you take a PPI
- Our perspective
- Weekly osteogenic loading at our Sacramento-area centers
- FAQ
- Sources
What PPIs are and why bone health comes up
PPIs switch off the acid-producing pumps in the stomach lining. Doctors prescribe them for reflux, ulcers and some other digestive conditions, and many people stay on them for years because symptoms return when they stop. Omeprazole is available over the counter in the US, so some people take it for long stretches without regular medical review.
Bone health enters the picture because stomach acid helps the body absorb certain forms of calcium. Lower acid could, in theory, mean less calcium reaching the bloodstream, and over time that could affect bone. Researchers have also looked at effects on bone-resorbing cells and on magnesium and vitamin B-12 levels. Theory is one thing and measured outcomes are another, which is why the research below needs a careful read.
What the fracture research shows
The most consistent signal is in fractures. A 2011 meta-analysis of 11 studies found PPIs modestly raised the risk of hip, spine and any-site fractures, while H2 blockers (a different class of acid reducer) were not significantly associated with higher risk. A 2018 updated meta-analysis reported an overall effect size of 1.28 (95% CI 1.22 to 1.35) for fracture incidence among PPI users, with risk trending upward from short-term to long-term use.
In plain terms, an effect size of 1.28 means roughly 28% higher relative odds of fracture in the studies pooled. That is a relative figure. Your own absolute risk depends on your age, sex, bone density, fall history and other medications. A small relative increase in someone at low baseline risk is a small absolute change. The same relative increase in someone who already has osteoporosis matters more.
The researchers behind the 2011 analysis made a point worth keeping in mind: because PPIs are so widely used, even a slight increase in individual risk could add up to a large number of extra fractures across the population.
Omeprazole specifically
Many readers search for omeprazole by name. A 2026 network meta-analysis in Frontiers in Pharmacology in older adults found omeprazole was associated with higher any-site fracture risk (OR 1.51, 95% CI 1.36 to 1.67) and hip fracture risk (OR 1.41, 95% CI 1.25 to 1.60). The authors also noted that a missing fracture signal for a drug should not be read as proof that it is safe for the skeleton, since fracture and bone-density findings do not always line up.
That last point cuts both ways. It means individual PPIs may differ, and it means the evidence is still being sorted out. It does not mean omeprazole is uniquely dangerous, and it does not justify stopping a drug that is controlling a real problem.
Dose and duration
The FDA labeling states that fracture risk was increased with high-dose therapy (multiple daily doses) and long-term therapy of a year or longer. A short course for a stomach ulcer is a different situation from a daily pill taken for a decade because no one revisited the prescription.
Does it actually reduce bone density?
Here the evidence is split, and that is the honest answer.
A 2021 meta-analysis by Aleraij and colleagues found a statistically significant reduction in bone mineral density among PPI users (mean difference of -0.03, 95% CI -0.04 to -0.01). A 2022 cohort study from South Korea found users prescribed a PPI for more than 180 days had a higher risk of osteoporosis in a pooled analysis of six databases (HR 1.57, 95% CI 1.28 to 1.92).
On the other side, a 2022 narrative review noted that several studies, including the Study of Osteoporotic Fractures and the Women’s Health Initiative, found no significant effect of PPI exposure on bone density change over time. The same review observed that the fracture link is only partly explained because the effect on bone density is inconsistent.
A 2024 umbrella review concluded that while findings connect PPIs with adverse bone outcomes, the certainty of most of the evidence is very low to low by GRADE criteria. The 2021 meta-analysis authors likewise called causality inconclusive even though many observational studies show higher fracture risk.
| Question | What the research suggests | How firm is it |
|---|---|---|
| Do PPI users fracture more often? | Modest increase in hip, spine and wrist fractures in many studies | Consistent in observational data, causation unproven |
| Does risk rise with dose and time? | Yes, higher with multiple daily doses and a year or more of use | Reflected in FDA labeling |
| Do PPIs lower bone density? | Small average decline in some meta-analyses, none in some large cohorts | Mixed |
| Do H2 blockers carry the same signal? | Not significantly associated in a 2011 meta-analysis | Older data |
Why correlation is not the whole story
People who take PPIs for years tend to be older, to have more chronic illness, to take more medications, and to be less active. Each of those independently raises fracture risk. Studies adjust for some of these factors but never all of them. That is a big reason causation remains uncertain, and why a Mendelian randomization analysis (a genetics-based method designed to reduce confounding) reported in 2026 found no compelling evidence for a causal link between PPI use and osteoporosis or fractures. Both things can be true: the association is real in the data, and the drug may not be the cause.
How PPIs might affect bone
The mechanisms researchers propose include reduced intestinal calcium absorption, interrupted function of osteoclasts (the cells that break down bone), and lower bone mineral density. None is proven in people at typical doses.
Magnesium is a more concrete concern. FDA labeling notes that low magnesium has been reported in patients treated with PPIs for at least three months, most often after a year of therapy. It can lead to low calcium or potassium and can worsen existing low calcium in at-risk patients. The labeling also says long-term acid suppression, for example beyond three years, may cause vitamin B-12 malabsorption. If you want the full picture of the mineral, see our guide on magnesium and bone health.
Who should pay closer attention
A PPI is more worth reviewing if you:
- have been diagnosed with osteopenia or osteoporosis
- have had a fragility fracture (a break from a fall at standing height or less)
- take the PPI at a high or twice-daily dose
- have taken a PPI daily for a year or longer
- also take other medicines linked to bone loss, such as long-term corticosteroids, or SSRIs (see our piece on SSRI bone loss)
- are postmenopausal, older, or have a low body weight
If several of these apply, the combined picture matters more than any single drug.
What to do if you take a PPI
Do not stop on your own
Reflux and ulcers cause real harm when untreated, and stopping some PPIs abruptly can bring on rebound symptoms. The FDA labeling says patients at risk for osteoporosis-related fractures should be managed according to established guidelines and use the lowest dose and shortest duration appropriate for their condition. The omeprazole medication guide gives the same advice to patients. So the useful conversation is about dose and duration, not about quitting.
Questions to bring to your prescriber
- Do I still have the condition this was prescribed for?
- Can I step down to a lower dose or take it only when needed?
- Would a different acid reducer or a lifestyle change work for my symptoms?
- Should my vitamin D, calcium, magnesium and B-12 be checked?
- Do I need a bone density scan or a fracture risk estimate?
When to ask about bone density testing
No guideline sets a special rule for PPI users, so this comes down to your overall risk. Current US screening advice from the USPSTF, as summarized by Henry Ford Health, recommends bone density scanning for women 65 and older and for postmenopausal women under 65 with at least one risk factor, such as low body weight, a prior fracture, a parent with a hip fracture, or smoking. Long-term PPI use is a reasonable reason to raise the topic with your clinician, particularly if you also meet one of those criteria, if you have lost height, or if you are a man over 70 with other risk factors. Your clinician decides whether a scan, a FRAX estimate, or both make sense.
Other side effects worth knowing
Bone is not the only issue. FDA labeling also lists C. difficile-associated diarrhea, B-12 deficiency, low magnesium, and cutaneous or systemic lupus among other serious risks. Diarrhea that does not improve should be reported to your doctor, and new rashes or joint symptoms should prompt a call as well.
Protecting bone while you take a PPI
These steps are sensible whether or not a PPI is the culprit. Confirm specifics with your clinician, especially if you have kidney disease or take other medicines.
- Get enough protein, calcium and vitamin D from food first. Our summary of protein and bone density covers how much matters. Some calcium forms depend on stomach acid more than others, so ask your doctor or pharmacist which form suits you if you need a supplement.
- Have magnesium and vitamin D levels checked if you have taken a PPI for a year or more.
- Do resistance and impact-style loading. Bone responds to mechanical force, which no pill replaces. Our evidence-based guide on how to increase bone density lays out the options.
- Reduce fall risk. Balance work, good lighting and vision checks matter because fractures need a fall or a force.
- Avoid smoking and heavy alcohol use, both of which independently harm bone.
If you have already been prescribed an osteoporosis drug and it is not working for you, our overview of bisphosphonate alternatives explains the other routes to discuss with your doctor.
Our perspective
We see many people who arrive with a diagnosis of osteopenia or osteoporosis and a long list of daily medications. A PPI is often on it, taken for years and rarely questioned. We do not tell anyone to change a prescription. That is a conversation for the prescriber who knows your history.
What we can say is that the research is honest about its limits: a modest fracture signal, mixed bone density data, and low certainty overall. That should lead to sensible review, not panic. The thing within your control is how much load your skeleton gets. Bone adapts to force, and many people with low bone mass have gone years without any meaningful stimulus.
Our approach is osteogenic loading: one brief, supervised session per week on specialized equipment, aimed at stimulating bone growth without drugs. It is a non-pharmaceutical protocol, so it sits alongside whatever your doctor has you taking. We recommend bringing your medication list to your first visit so we can work with your care team’s guidance, and we encourage you to keep your physician informed about what you are doing.
— Aaron
Weekly osteogenic loading at our Sacramento-area centers
If your bones are a concern and you want an active step to take beyond medication review, our centers in Rancho Cordova, El Dorado Hills and Granite Bay offer supervised osteogenic loading sessions once per week. Each session is short, guided by our staff, and designed to be measurable, so you can see how your strength changes over time.
You can read how the approach works and what the studies report in our guide to weekly osteogenic loading for osteoporosis, then contact your nearest center through our main page to ask whether it suits you. We also offer red light therapy, PEMF mats, BioCharger, compression therapy, vibration plates and hydromassage lounges for recovery and wellness.
FAQ
Does omeprazole cause bone loss?
Omeprazole is associated with a higher fracture risk in several studies, including a 2026 network meta-analysis in older adults. Evidence that it directly lowers bone density is mixed, and most reviews rate the certainty as low. Ask your prescriber whether your dose and duration are still necessary.
How long can you take a PPI before bone risk goes up?
The FDA labeling points to higher fracture risk with multiple daily doses and with therapy lasting a year or longer. Risk in the studies trends upward from short-term to long-term use. That is a reason to review the prescription regularly, not a hard cutoff.
Should I stop my PPI if I have osteoporosis?
Not without talking to your prescriber. Untreated reflux or ulcers carry their own risks, and stopping abruptly can cause rebound symptoms. Your clinician may lower the dose, change the schedule, or switch strategies while monitoring your bones.
Are H2 blockers safer for bones than PPIs?
In a 2011 meta-analysis, H2 blockers were not significantly associated with higher fracture risk, unlike PPIs. That data is older and observational, so it does not prove they are safer for you. Whether an H2 blocker can control your symptoms is a question for your doctor.
Can exercise offset PPI-related bone loss?
No study proves it offsets a PPI effect specifically, but mechanical loading is one of the best-supported ways to support bone in general. Supervised resistance and osteogenic loading programs are options to discuss with your clinician.
Sources
- FDA prescribing information for PPI therapy (2023)
- Omeprazole medication guide, DailyMed
- Proton-pump Inhibitor Use and Fracture Risk: An Updated Meta-analysis (2018)
- Effect of proton pump inhibitors on bone mineral density: a meta-analysis
- Long-term proton pump inhibitor use and risk of osteoporosis (2022)
- Proton pump inhibitors and risk of fractures: a meta-analysis (2011)
- Proton Pump Inhibitors and Bone Health: An Update Narrative Review (2022)
- Osseous implications of proton pump inhibitor therapy: an umbrella review (2024)
- Differential fracture risk among proton pump inhibitors, Frontiers in Pharmacology (2026)
- Osteoporosis screening guidelines, Henry Ford Health